Penumbra Inc.

PEN | NYSE

Price Alert Chart Builder DCF Calculator

$317.32

-$0.31 (-0.10%)

Sep 21, 2026, 9:36 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.10%

(1D)

Rating

Updated: Aug 11, 2026

50.1

Fundamentals Average

Market Sentiment Neutral

Moat Narrow

Full Analysis

Key Statistics

Market Data

Market Cap $12.5B

1D Range

316.77 317.50

52W Range

221.26 362.41

Valuation (TTM)

PE 78.03

PB 8.17

EV/EBITDA 59.36

Valuation (NTM)

Forward PE 50.70

Forward PEG 2.85

Price Target $320

Cash Flow

FCF Yield 1.7%

SBC Adj. FCF Yield 1.3%

SBC Impact -27.6%

Margins

Gross Margin 67.8%

Operating Margin 12.4%

FCF Margin 14.3%

Growth (CAGR)

Revenue 3Y | 5Y 17.1% | 17.5%

Dil EPS 3Y | 5Y 76.5% | 56.8%

FCF 3Y | 5Y 650.9% | 75.1%

Returns

ROA 8.1%

ROE 11.1%

ROIC 8.4%

Financial Health

Net Debt

$7.44M

Current Ratio 5.75

Interest Coverage 144.22

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; ...

Sector Healthcare

Industry Medical - Devices

Employees 4,700

IPO Date Sep 17, 2015

Website www.penumbrainc.com

Fiscal Year January - December

Full Company Profile

Latest News

5 days ago · zacks.com

Reasons to Retain Penumbra Stock in Your Portfolio for Now

PEN's portfolio expansion and international growth support momentum, while rising costs, FX exposure and margin pressure remain key risks.

2 months ago · prnewswire.com

Penumbra, Inc. Reports Second Quarter 2026 Financial Results

ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.

2 months ago · gurufocus.com

THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care

THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care PR Newswire ALAMEDA, Cal

3 months ago · prnewswire.com

First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke

ALAMEDA, Calif., July 7, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the initiation of its FORWARD study, an international, real world prospective, multi-center study.

3 months ago · zacks.com

Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?

PEN gains CE Mark in Europe for THUNDERBOLT, expanding stroke treatment access and advancing its global stroke care strategy.

3 months ago · prnewswire.com

Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT

The THUNDERBOLT TM Computer Assisted Vacuum Thrombectomy (CAVT TM ) technology introduces modulated aspiration for acute ischemic stroke for the first time, enabling more rapid, complete clot removal ALAMEDA, Calif., June 15, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced it has secured CE Mark in Europe for THUNDERBOLT™, further laying the groundwork for launching computer assisted vacuum thrombectomy (CAVT™) technology to address acute ischemic stroke globally.

3 months ago · prnewswire.com

Penumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke

THUNDERBOLT is the first CAVT platform to deliver modulated aspiration for acute ischemic stroke — enabling faster, more complete clot removal ALAMEDA, Calif., June 11, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced it has received U.S. Food and Drug Administration (FDA) clearance for THUNDERBOLT™, expanding its computer assisted vacuum thrombectomy (CAVT™) technology to address acute ischemic stroke.

4 months ago · zacks.com

Why Is Penumbra (PEN) Down 1.2% Since Last Earnings Report?

Penumbra (PEN) reported earnings 30 days ago. What's next for the stock?

5 months ago · zacks.com

Penumbra (PEN) Misses Q1 Earnings Estimates

Penumbra (PEN) came out with quarterly earnings of $0.82 per share, missing the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $0.83 per share a year ago.